Adalimumab Total Anti-drug Antibody ELISA (IDKmonitor®)

Product code: K9651 (96 wells)

Determination of total anti-adalimumab antibodies

Adalimumab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation, which is a major cause of loss of drug response. The IDKmonitor Adalimumab Total Anti-drug ELISA kit is a ‘drug tolerant’ assay that enables the detection of anti-drug antibodies in the presence of circulating drug.

The assay is widely available throughout the UK and Ireland to both routine clinical laboratories as well as for research applications. Please contact us for your nearest test reference laboratory. This kit is supported by UK publications and evidence base.

Download Brochure
Technical Support
Request a Quote

Key Advantages

Supports the investigation of primary non-response and loss of response to adalimumab
Highly sensitive drug tolerant assay that detects total anti-adalimumab antibodies (those free and bound to adalimumab)
May help to predict long term outcome of disease
Identifies patients with low-titre anti-adalimumab antibodies
Applicable to both gastroenterology and rheumatology
Automatable on ELISA automates (e.g. Dynex D2)

Specifications

ELISA

45 tests

Storage: 2-8 °C

Blood sample

Related Products

    076-20-TurbiPEL-Faecal-Pancreatic-Elastase-turbidimetric-assay

    Adalimumab Drug Level ELISA (IDKmonitor®)

    Adalimumab is a recombinant protein used to treat inflammatory bowel disease (IBD). The IDKmonitor Adalimumab Drug Level ELISA kit is a microplate-based quantitative sandwich ELISA for the determination of free therapeutic TNFα antibodies (adalimumab) from plasma or serum samples.

    076-20-Adalimumab-Free-Anti-drug-ELISA-IDKmonitor

    Adalimumab Free Anti-drug Antibody ELISA (IDKmonitor®)

    Adalimumab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation, which is a major cause of loss of drug response.